Betamethasone (as 17- valerate) 0.1% and Neomycin sulphate 0.5%.
Betavate-N preparations are indicated for the treatment of the following conditions where secondary bacterial infection is present, suspected, or likely to occur: eczema in children and adults, including atopic and discoid eczema, prurigo nodularis; psoriasis (excluding widespread plaque psoriasis). neurodermatoses, seborrhoeic dermatitis, contact sensitivity reactions and it may be used as an adjunct to systemic steroid therapy in generalised erythroderma. This preparation can also be used in the management of secondarily infected insect bites and anal and genital intertrigo.
Betamethasone (as 17- valerate) 0.1% and Neomycin sulphate 0.5%.
Betavate-N preparations are indicated for the treatment of the following conditions where secondary bacterial infection is present, suspected, or likely to occur: eczema in children and adults, including atopic and discoid eczema, prurigo nodularis; psoriasis (excluding widespread plaque psoriasis). neurodermatoses, seborrhoeic dermatitis, contact sensitivity reactions and it may be used as an adjunct to systemic steroid therapy in generalised erythroderma. This preparation can also be used in the management of secondarily infected insect bites and anal and genital intertrigo.
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.